7.05
Precedente Chiudi:
$7.09
Aprire:
$7.02
Volume 24 ore:
88,626
Relative Volume:
1.06
Capitalizzazione di mercato:
$61.55M
Reddito:
$123.24M
Utile/perdita netta:
$136.00K
Rapporto P/E:
-352.50
EPS:
-0.02
Flusso di cassa netto:
$-148.99M
1 W Prestazione:
-8.08%
1M Prestazione:
-25.00%
6M Prestazione:
-64.03%
1 anno Prestazione:
-63.81%
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Confronta MCRB con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MCRB
Seres Therapeutics Inc
|
7.05 | 66.98M | 123.24M | 136.00K | -148.99M | -0.02 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
2023-06-26 | Ripresa | Oppenheimer | Outperform |
2023-04-21 | Iniziato | JP Morgan | Neutral |
2021-07-23 | Downgrade | Goldman | Neutral → Sell |
2021-05-18 | Ripresa | Goldman | Neutral |
2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
2020-08-18 | Iniziato | Piper Sandler | Overweight |
2020-08-11 | Reiterato | H.C. Wainwright | Buy |
2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
2019-04-30 | Iniziato | Jefferies | Hold |
2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
2017-10-13 | Iniziato | Oppenheimer | Outperform |
2017-08-04 | Reiterato | H.C. Wainwright | Buy |
2017-02-01 | Reiterato | FBR & Co. | Outperform |
2016-08-12 | Reiterato | FBR Capital | Outperform |
2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
2016-08-01 | Reiterato | H.C. Wainwright | Buy |
2016-07-29 | Ripresa | H.C. Wainwright | Buy |
2016-03-30 | Iniziato | FBR Capital | Outperform |
2016-03-03 | Iniziato | Guggenheim | Buy |
2016-01-25 | Iniziato | H.C. Wainwright | Buy |
2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2015-07-22 | Iniziato | Canaccord Genuity | Buy |
2015-07-21 | Iniziato | Goldman | Neutral |
2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World
Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus
Seres Therapeutics reports promising biomarker data - Investing.com
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq
Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts
Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com
Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com
MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus
Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus
Seres Therapeutics Inc Qtrly EPS $3.76 - marketscreener.com
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025 - The Globe and Mail
Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) PT at $80.00 - Defense World
Seres Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
5 Best Microbiome Companies (May 2025) - Securities.io
Seres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.com - Defense World
Seres Therapeutics Reveals Game-Changing Biomarkers for IBD Treatment, Seeks Development Partners - Stock Titan
Seres Therapeutics (MCRB) to Unveil New Findings at 2025 Digesti - GuruFocus
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases - The Manila Times
Investor’s Delight: Seres Therapeutics Inc (MCRB) Closes Weak at 0.70, Down -2.90 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - Defense World
MCRB Stock Update: Seres Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
Seres Therapeutics Inc (MCRB) expanding its growth trajectory ahead - Sete News
Petri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock split - The Business Journals
Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan
Seres Therapeutics enacts 1-for-20 reverse stock split By Investing.com - Investing.com Canada
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):